Abstract：
We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.
摘要：
我们调查了从猕猴的莫努比拉韦和尼马特雷韦/利托那韦联合治疗中收集的样品中严重急性呼吸综合征冠状病毒2的突变谱。我们发现，莫诺比拉韦诱导了一些低丰度的尼马特雷韦抗性突变，这些突变在联合治疗中未被进一步选择。尼马特雷韦/利托那韦的共同给药降低了莫诺比拉韦的诱变作用。
